 |
|
Invasive Methicillin-Resistant Staphylococcus aureus Infections in the United States
R. Monina Klevens, DDS, MPH;
Melissa A. Morrison, MPH;
Joelle Nadle, MPH;
Susan Petit, MPH;
Ken Gershman, MD, MPH;
Susan Ray, MD;
Lee H. Harrison, MD;
Ruth Lynfield, MD;
Ghinwa Dumyati, MD;
John M. Townes, MD;
Allen S. Craig, MD;
Elizabeth R. Zell, MSTAT;
Gregory E. Fosheim, MPH;
Linda K. McDougal, MS;
Roberta B. Carey, PhD;
Scott K. Fridkin, MD; for the Active Bacterial Core surveillance (ABCs) MRSA Investigators
JAMA. 2007;298:1763-1771.
Context As the epidemiology of infections with methicillin-resistant Staphylococcus aureus (MRSA) changes, accurate information on the scope and magnitude of MRSA infections in the US population is needed.
Objectives To describe the incidence and distribution of invasive MRSA disease in 9 US communities and to estimate the burden of invasive MRSA infections in the United States in 2005.
Design and Setting Active, population-based surveillance for invasive MRSA in 9 sites participating in the Active Bacterial Core surveillance (ABCs)/Emerging Infections Program Network from July 2004 through December 2005. Reports of MRSA were investigated and classified as either health care–associated (either hospital-onset or community-onset) or community-associated (patients without established health care risk factors for MRSA).
Main Outcome Measures Incidence rates and estimated number of invasive MRSA infections and in-hospital deaths among patients with MRSA in the United States in 2005; interval estimates of incidence excluding 1 site that appeared to be an outlier with the highest incidence; molecular characterization of infecting strains.
Results There were 8987 observed cases of invasive MRSA reported during the surveillance period. Most MRSA infections were health care–associated: 5250 (58.4%) were community-onset infections, 2389 (26.6%) were hospital-onset infections; 1234 (13.7%) were community-associated infections, and 114 (1.3%) could not be classified. In 2005, the standardized incidence rate of invasive MRSA was 31.8 per 100 000 (interval estimate, 24.4-35.2). Incidence rates were highest among persons 65 years and older (127.7 per 100 000; interval estimate, 92.6-156.9), blacks (66.5 per 100 000; interval estimate, 43.5-63.1), and males (37.5 per 100 000; interval estimate, 26.8-39.5). There were 1598 in-hospital deaths among patients with MRSA infection during the surveillance period. In 2005, the standardized mortality rate was 6.3 per 100 000 (interval estimate, 3.3-7.5). Molecular testing identified strains historically associated with community-associated disease outbreaks recovered from cultures in both hospital-onset and community-onset health care–associated infections in all surveillance areas.
Conclusions Invasive MRSA infection affects certain populations disproportionately. It is a major public health problem primarily related to health care but no longer confined to intensive care units, acute care hospitals, or any health care institution.
Author Affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia (Drs Klevens, Carey, and Fridkin and Mss Morrison, Zell, and McDougal and Mr Fosheim); California Emerging Infections Program, Oakland (Ms Nadle); Connecticut Department of Health, Hartford (Ms Petit); Colorado Emerging Infections Program, Denver (Dr Gershman); Grady Memorial Hospital, Atlanta (Dr Ray); Maryland Emerging Infections Program and Johns Hopkins Bloomberg School of Public Health, Baltimore (Dr Harrison); Minnesota Department of Health, Minneapolis (Dr Lynfield); University of Rochester, Rochester General Hospital, Rochester, New York (Dr Dumyati); Oregon Health & Science University, Portland (Dr Townes); and Tennessee Department of Health, Nashville (Dr Craig).
RELATED LETTERS
Determining Whether Methicillin-Resistant Staphylococcus aureus Is Associated With Health Care
Michael Z. David, Jane D. Siegel, Henry F. Chambers, and Robert S. Daum
JAMA. 2008;299(5):519.
EXTRACT
| FULL TEXT
Determining Whether Methicillin-Resistant Staphylococcus aureus Is Associated With Health Care—Reply
R. Monina Klevens, Melissa A. Morrison, and Scott K. Fridkin
JAMA. 2008;299(5):519-520.
EXTRACT
| FULL TEXT
RELATED ARTICLES
Antimicrobial Resistance: It's Not Just for Hospitals
Elizabeth A. Bancroft
JAMA. 2007;298(15):1803-1804.
EXTRACT
| FULL TEXT
MRSA Infections
John L. Zeller, Alison E. Burke, and Richard M. Glass
JAMA. 2007;298(15):1826.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Restoration of Susceptibility of Methicillin-resistant Staphylococcus aureus to {beta}-Lactam Antibiotics by Acidic pH: ROLE OF PENICILLIN-BINDING PROTEIN PBP 2a
Lemaire et al.
J. Biol. Chem. 2008;283:12769-12776.
ABSTRACT
| FULL TEXT
Susceptibility of Staphylococcus aureus isolated from skin and wound infections in the United States 2005-07: laboratory-based surveillance study
Tillotson et al.
J Antimicrob Chemother 2008;0:dkn149v1-7.
ABSTRACT
| FULL TEXT
Staphylococcus aureus--Probing for Host Weakness?
Camargo and Gilmore
J. Bacteriol. 2008;190:2253-2256.
FULL TEXT
Role of Staphylococcus aureus Catalase in Niche Competition against Streptococcus pneumoniae
Park et al.
J. Bacteriol. 2008;190:2275-2278.
ABSTRACT
| FULL TEXT
Over the counter medicines: proceed with caution
Ferner and Beard
BMJ 2008;336:694-696.
FULL TEXT
Universal Surveillance for Methicillin-Resistant Staphylococcus aureus in 3 Affiliated Hospitals
Robicsek et al.
ANN INTERN MED 2008;148:409-418.
ABSTRACT
| FULL TEXT
Expanding the Universe of Methicillin-Resistant Staphylococcus aureus Prevention
Lautenbach
ANN INTERN MED 2008;148:474-476.
FULL TEXT
Preventing MRSA Infections: Finding It Is Not Enough
Diekema and Climo
JAMA 2008;299:1190-1192.
FULL TEXT
A Cholesterol Biosynthesis Inhibitor Blocks Staphylococcus aureus Virulence
Liu et al.
Science 2008;319:1391-1394.
ABSTRACT
| FULL TEXT
Sortase as a Target of Anti-Infective Therapy
Maresso and Schneewind
Pharmacol. Rev. 2008;60:128-141.
ABSTRACT
| FULL TEXT
An antidote for Staphylococcus aureus pneumonia?
DeLeo and Otto
J. Exp. Med. 2008;205:271-274.
ABSTRACT
| FULL TEXT
Relationships between vancomycin pharmacodynamics and the emergence of vancomycin-intermediate Staphylococcus aureus (VISA) from heterogeneous VISA in an in vitro pharmacodynamic model
Rose et al.
J Antimicrob Chemother 2008;0:dkn037v1-6.
ABSTRACT
| FULL TEXT
Determining Whether Methicillin-Resistant Staphylococcus aureus Is Associated With Health Care
David et al.
JAMA 2008;299:519-519.
FULL TEXT
Protecting Your Patients, Colleagues, Family, and Yourself From Infection: First Wash
Alspach
Crit Care Nurse 2008;28:7-12.
FULL TEXT
From the Cover: Epidemic community-associated methicillin-resistant Staphylococcus aureus: Recent clonal expansion and diversification
Kennedy et al.
Proc. Natl. Acad. Sci. USA 2008;105:1327-1332.
ABSTRACT
| FULL TEXT
A 39-Year-Old Man With a Skin Infection
Moellering
JAMA 2008;299:79-87.
ABSTRACT
| FULL TEXT
Community acquired MRSA in Europe
Ferry and Etienne
BMJ 2007;335:947-948.
FULL TEXT
Invasive MRSA Infections
JWatch Emergency Med. 2007;2007:2-2.
FULL TEXT
The Epidemiology of MRSA
Journal Watch Dermatology 2007;2007:1-1.
FULL TEXT
MRSA in the U.S.
JWatch Infect. Diseases 2007;2007:2-2.
FULL TEXT
New Worries About Multidrug-Resistant Bacteria
JWatch General 2007;2007:2-2.
FULL TEXT
Antimicrobial Resistance: It's Not Just for Hospitals
Bancroft
JAMA 2007;298:1803-1804.
FULL TEXT
|
